RxDoctor Payments DataLook up a doctor →

Blair Budden, MD

Dermatology · Lafayette, LANPI 1831458363

Payments from drug & device makers

$329,078in general payments, 2019–2025

Across 962 payments — averaging $342.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$214K
  • AbbVie$57K
  • Sun Pharmaceutical Industries Inc.$26K
  • Organon$24K
  • Novartis$1K
  • Johnson & Johnson$978
  • plus $6K from 30 others

What the payments were for

  • Consulting fees$2,7001%
  • Speaking & faculty fees$256,55778%
  • Travel & lodging$50,78215%
  • Food & beverage$18,4676%
  • Education$5710%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$329,078 in reported general payments places this provider in the 90th percentile of 189 dermatology providers in Louisiana.

See all dermatology providers in Louisiana

Medicare billing

Part B allowed, 2024
$816,531
Medicare patients
1,592
Services billed
11,464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa31$647,689
Taltz AutoinjectorIxekizumab66$505,574
Dupixent PenDupilumab80$315,745
OtezlaApremilast48$235,706
Dupixent SyringeDupilumab16$62,616
XolairOmalizumab11$35,374
Ketoconazole489$7,506
Fluocinonide229$7,269
Betamethasone Dipropionate118$5,195
Triamcinolone Acetonide465$5,098
Fluorouracil78$5,045
Tacrolimus33$3,769
Doxycycline Hyclate151$3,581
Mycophenolate Mofetil46$3,498
Calcipotriene15$2,717

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$442$235,70648 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 189 dermatology providers in Louisiana.

Other dermatology in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →